--- title: "TriGemX Bio Raises $94M to Run Phase 3 Migraine Trials" description: "TriGemX Bio, formerly Kallyope, closed $94 million to fund Phase 3 trials of elismetrep, an investigational oral TRPM8 blocker for acute migraine treatment." date: 2026-10-01T00:00:00.000Z source: https://venturecapitaltracker.com/trigemx-bio-raises-94m-phase-3-migraine-trials --- # TriGemX Bio Raises $94M to Run Phase 3 Migraine Trials > TriGemX Bio, formerly Kallyope, closed $94 million to fund Phase 3 trials of elismetrep, an investigational oral TRPM8 blocker for acute migraine treatment. TriGemX Bio has closed **$94 million of financing** to advance elismetrep through Phase 3 trials for the acute treatment of migraine. The company did not assign a conventional venture stage to the round. **The Column Group, TCGX and Viking Global Investors** co-led the financing. The raise coincides with Kallyope's relaunch as TriGemX Bio and the appointment of Jeff Goater as chief executive and Aninda Katragadda as chief financial officer. This is a late-stage clinical financing rather than a platform-building round. Most of the value now rests on whether elismetrep can reproduce its Phase 2 signal in large pivotal studies and offer a useful alternative to established migraine drugs. ## What is elismetrep? Elismetrep, also known as K-304, is an investigational oral blocker of **TRPM8**, an ion channel involved in sensory signaling. TriGemX is developing it as an acute treatment taken when a migraine attack begins. The mechanism is different from today's CGRP-targeted drugs and from triptans. Mechanistic novelty can be valuable if it serves patients who do not obtain adequate relief from existing options, but a novel target does not guarantee clinical differentiation. TriGemX says a Phase 2b study showed elismetrep was well tolerated and reduced migraine pain and associated symptoms. Those findings motivated the pivotal program. The drug remains investigational and has not been approved by the FDA or another regulator. ## The Phase 3 program The company says three studies are part of the late-stage program: - A first pivotal trial, identified as **NCT07645924**. - A long-term safety study, **NCT07674654**. - A second pivotal study, **NCT07816367**, scheduled to begin in October 2026. Initial results from the first pivotal trial are expected in **mid-2027**. The financing therefore buys time to reach a specific, potentially value-changing milestone. It also concentrates risk. Phase 3 studies are larger and more expensive than mid-stage trials, and modest differences in efficacy, safety, adherence or statistical assumptions can determine whether a program succeeds. ## Why migraine remains a meaningful market Migraine is common, disabling and heterogeneous. Acute treatments include generic triptans, CGRP antagonists such as AbbVie's Ubrelvy and Pfizer's Nurtec ODT, and other mechanisms including Eli Lilly's Reyvow. These products have improved care, but no single treatment works adequately for every patient. Doctors may also need alternatives because of contraindications, tolerability or inconsistent response. TriGemX's commercial opportunity is not simply that migraine is large. It is that a mechanistically distinct oral option could find a place in treatment algorithms if it delivers fast, reliable relief with an acceptable safety profile and convenient formulation. The company has moved to a liquid-filled soft-gel formulation, which it describes as part of elismetrep's differentiated profile. Phase 3 data will need to show whether the formulation produces clinically meaningful benefits rather than just technical novelty. ## What the relaunch changes The name TriGemX refers to the trigeminal ganglion, a migraine-relevant neural structure where TRPM8 is expressed. The change from Kallyope narrows the company's public identity around one lead program. That focus can be positive: capital, management attention and messaging are aligned with the pivotal asset. It also reduces diversification. A setback in elismetrep would have an outsized effect on the company because the new strategy is tightly centered on that molecule. New chief executive Jeff Goater brings experience from The Column Group, Surface Oncology and Voyager Therapeutics. CFO Aninda Katragadda has held finance roles across multiple biotechnology companies. Their immediate priorities are likely to include trial execution, cash planning, regulatory preparation and eventual commercial or partnership strategy. ## How to evaluate the program The most important questions extend beyond whether the primary endpoint is statistically significant: 1. How quickly does pain relief begin, and how durable is the effect? 2. What share of patients achieves freedom from pain and the most bothersome symptom? 3. How does performance vary across patients who did not respond to CGRP drugs or triptans? 4. Are there safety, tolerability or functional restrictions that limit use? 5. Can the drug be manufactured and priced competitively in a market with branded and generic options? TriGemX has not disclosed the financing's valuation or expected cash runway. The $94 million should carry the program toward major data, but Phase 3 execution, regulatory work and pre-commercial planning can consume substantial capital. ## Bottom line TriGemX's financing is a clear clinical bet: **$94 million to test whether TRPM8 blockade can become a new acute migraine mechanism**. The round has experienced specialist investors and a near-term milestone in mid-2027. Until those results arrive, elismetrep should be viewed as a promising but unapproved late-stage asset. The opportunity is meaningful because many patients still lack adequate relief; the risk is equally concentrated because the relaunch now depends heavily on one pivotal program. **By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy) **Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.